Bortezomib beneficial in graft-versus-host disease prophylaxis
(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from a prophylactic, ...
Aug 8, 2012
0
0